250 related articles for article (PubMed ID: 22154617)
1. Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer.
Tan C; Xu HY; Zhang CY; Zhang H; Chen CM; Zhang WM; Sun XY; Jin YT
Arch Med Res; 2011 Nov; 42(8):669-76. PubMed ID: 22154617
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer.
Goto I; Yoneda S; Yamamoto M; Kawajiri K
Cancer Res; 1996 Aug; 56(16):3725-30. PubMed ID: 8706015
[TBL] [Abstract][Full Text] [Related]
4. Risk for K-ras gene mutations in smoking-induced lung cancer is associated with cytochrome P4501A1 and glutathione S-transferase micro1 polymorphisms.
Noda N; Matsuzoe D; Konno T; Kawahara K; Yamashita Y; Shirakusa T
Oncol Rep; 2004 Oct; 12(4):773-9. PubMed ID: 15375499
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.
Sanchez-Cespedes M; Reed AL; Buta M; Wu L; Westra WH; Herman JG; Yang SC; Jen J; Sidransky D
Oncogene; 1999 Oct; 18(43):5843-9. PubMed ID: 10557071
[TBL] [Abstract][Full Text] [Related]
6. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
[TBL] [Abstract][Full Text] [Related]
7. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer.
Kawajiri K; Eguchi H; Nakachi K; Sekiya T; Yamamoto M
Cancer Res; 1996 Jan; 56(1):72-6. PubMed ID: 8548778
[TBL] [Abstract][Full Text] [Related]
8. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer.
Kim DH; Nelson HH; Wiencke JK; Zheng S; Christiani DC; Wain JC; Mark EJ; Kelsey KT
Cancer Res; 2001 Apr; 61(8):3419-24. PubMed ID: 11309302
[TBL] [Abstract][Full Text] [Related]
9. [Correlation between RARbeta gene promoter methylation and P53 gene mutations in non-small cell lung cancer].
Tan C; Jin YT; Xu HY; Zhang CY; Zhang H; Zhang WM; Chen CM; Sun XY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Apr; 29(2):131-6. PubMed ID: 22487818
[TBL] [Abstract][Full Text] [Related]
10. [CYP1A1 polymorphisms, lack of glutathione S-transferase M1 (GSTM1), cooking oil fumes and lung cancer risk in non-smoking women].
Zhu XX; Hu CP; Gu QH
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Nov; 33(11):817-22. PubMed ID: 21211368
[TBL] [Abstract][Full Text] [Related]
11. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L
Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194
[TBL] [Abstract][Full Text] [Related]
12. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer.
Kim DH; Nelson HH; Wiencke JK; Christiani DC; Wain JC; Mark EJ; Kelsey KT
Oncogene; 2001 Mar; 20(14):1765-70. PubMed ID: 11313923
[TBL] [Abstract][Full Text] [Related]
13. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
[TBL] [Abstract][Full Text] [Related]
14. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
Nie Q; Yang XN; An SJ; Zhang XC; Yang JJ; Zhong WZ; Liao RQ; Chen ZH; Su J; Xie Z; Wu YL
Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658
[TBL] [Abstract][Full Text] [Related]
15. CYP1A1 Ile462Val and MPO G-463A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung.
Larsen JE; Colosimo ML; Yang IA; Bowman R; Zimmerman PV; Fong KM
Carcinogenesis; 2006 Mar; 27(3):525-32. PubMed ID: 16195240
[TBL] [Abstract][Full Text] [Related]
16. Influence of polymorphism at p53, CYP1A1 and GSTM1 loci on p53 mutation and association of p53 mutation with prognosis in lung cancer.
Wang YC; Chen CY; Wang HJ; Chen SK; Chang YY; Lin P
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):402-10. PubMed ID: 10418172
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutation, allelism and survival in non-small cell lung cancer.
Nelson HH; Wilkojmen M; Marsit CJ; Kelsey KT
Carcinogenesis; 2005 Oct; 26(10):1770-3. PubMed ID: 15905205
[TBL] [Abstract][Full Text] [Related]
18. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage.
Chan EC; Lam SY; Tsang KW; Lam B; Ho JC; Fu KH; Lam WK; Kwong YL
Clin Cancer Res; 2002 Dec; 8(12):3741-6. PubMed ID: 12473584
[TBL] [Abstract][Full Text] [Related]
19. Associations between polymorphisms in DNA repair genes and TP53 mutations in non-small cell lung cancer.
Cho S; Kim MJ; Choi YY; Yoo SS; Lee WK; Lee EJ; Jang EJ; Bae EY; Jin G; Jeon HS; Lee SY; Cha SI; Park TI; Kim CH; Park JY
Lung Cancer; 2011 Jul; 73(1):25-31. PubMed ID: 21129811
[TBL] [Abstract][Full Text] [Related]
20. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer.
Kim DH; Kim JS; Ji YI; Shim YM; Kim H; Han J; Park J
Cancer Res; 2003 Jul; 63(13):3743-6. PubMed ID: 12839968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
